SAN DIEGO, May 26, 2016 /PRNewswire/ -- Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced members of the company's management team will participate on a panel discussing the intersection of immuno, viral and gene-based therapies for cancer treatment and present a corporate overview at the 2016 BIO International Convention, to be held June 6-9 in San Francisco.
In addition, Tocagen will participate in a panel discussion at the Boston CEO Conference, to be held May 31-June 1 in Boston, providing insight into the promises and challenges of gene therapy.
Details of the panel and presentation at the 2016 BIO International Convention are as follows:
Panel Title: Lighting the Match on Cancer: The Intersection of Immuno, Viral and Gene Therapy and the Implications for Cancer Treatment
Date and Time: Thursday, June 9, 9:00-10:15 a.m. PT
Location: West 3002
Participant: Asha Das, M.D., vice president, clinical development and medical affairs at Tocagen
Title: Tocagen Inc. Company Presentation
Date and Time: Wednesday, June 8, 5:00-5:13 p.m. PT
Location: Room 4
Speaker: Nicholas Boyle, Ph.D., vice president, business development and marketing at Tocagen
Details of the panel at Boston CEO Conference are as follows:
Panel Title: Genetic Therapies: The Promise and The Challenge
Date and Time: Wednesday, June 1, 1:30-2:00 p.m. ET
Participant: Harry Gruber, M.D., president and chief executive officer of Tocagen
About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer from within. The company is developing its lead investigational product candidate, Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine), initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. In 2016, Tocagen plans to initiate clinical trials of Toca 511 & Toca FC in patients with metastatic colorectal, pancreatic, breast, lung, renal and melanoma cancers and in patients with newly diagnosed HGG. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration, for Toca 511 & Toca FC for the treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma (GBM), a subset of HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information, visit www.tocagen.com or follow @Tocagen.
SOURCE Tocagen Inc.